Merck & Co. stock trades at USD 148.74 after pipeline updates
AD HOC NEWS
Merck & Co. stock was trading at USD 148.74 on September 25, 2026, driven by recent pipeline updates, including FDA approval for WELIREG plus LENVIMA and positive results from the BRUNELLO study. The company reported strong Q2 2026 worldwide sales of USD 16.6 billion, exceeding consensus estimates. Analysts, like Guggenheim, have raised target prices to USD 170 with a Buy rating, despite potential future competition for Keytruda.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.